The relative risk for all ATM pathogenic variant carriers was 2.03 (95% CI: 1.89–2.19) for ductal invasive breast cancer, 2.58 (95% CI: 1.93–3.44) for prostate cancer, 1.57 (95% CI: 1.35–1.83) for ovarian cancer, 1.49 (95% CI: 1.24–1.79) for colorectal cancer, and 4.21 (95% CI: 3.24–5.47) for pancreatic cancer [59]. Here, ATM is linked to prostate carcinoma.